Home / Locations / ProMed Innovations (Affiliate Site)
ProMed Innovations (Affiliate Site)
About This Site
Located in Catford, Southeast London, our affiliate partner, ProMed Innovations, extends Bioluminux’s clinical research capabilities to a diverse urban population. Led by Dr. Olaleye Oginni, an experienced General Practitioner and healthcare leader, the site combines extensive primary care experience with dedicated clinical research capabilities.
The site supports clinical trials across major therapeutic areas, including vaccines and infectious diseases, dermatology, cardiovascular disease, endocrinology and metabolic disorders, respiratory disease, CNS and mental health conditions, and general medicine.
With experienced investigators, dedicated research professionals, strong community engagement, and connections with local healthcare providers, the Catford site provides broad patient access and strong recruitment potential. Through this affiliation, Bioluminux expands its geographic reach and patient access while maintaining a shared commitment to quality, participant-centered research, and responsive collaboration with sponsors and CROs.
Research Leadership
Dr Olaleye Oginni MBChB, MRCGP, DFSRH, DRCOG, PGcert(Med Ed.), CCT - General Practitioner(GP)
CEO /Site Lead/GP
Specialty:
Dr Adeola Oginni MBChB, MRCGP, DFRSH, CCT - General Practitioner(GP)
Principal Investigator/GP
Specialty:
Dr Kazeem Salako MBBS, FRCP, Dip (Lead & Mgt), CCT - Dermatology
Principal Investigator/Dermatologist
Specialty:
Site Facilities & Amenities
Recruiting Studies At This Location
COPD and Common Colds Research Study
To investigate whether an antiviral medicine can reduce symptoms and COPD flare-ups caused by rhinovirus, a common cold virus.
Hypertension Study
To evaluate whether the investigational treatment reduces the risk of major cardiovascular events in adults with uncontrolled hypertension.
Opioid Dependence Recovery Research Study
To investigate whether adding an investigational medicine to buprenorphine treatment can help reduce opioid use during recovery.